{"filings":[{"id":92639,"accession_number":"0001437749-26-015621","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotech Q1 net loss $3.8M; raises 2026 revenue and net income guidance on NERLYNX demand","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 product revenue $42.0M vs $43.1M YoY; GAAP net loss $3.8M ($0.07/share) vs net income $3.0M.","Non-GAAP adjusted net loss $1.9M ($0.04/share) vs adjusted net income $5.0M ($0.10) YoY.","FY 2026 guidance raised: net product revenue $202-206M (prior $194-198M); net income $16-19M (prior $10-13M).","Debt fully repaid on May 4, 2026; cash & securities $101.5M at March 31, 2026, up from $97.5M.","Second-quarter Q2 2026 net product revenue guidance $50-52M, net income $2-4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":44814000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103612,"accession_number":"0001437749-26-005869","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotechnology Q4 2025 revenue $75.5M, GAAP net income $13.4M; guides FY2026 net income $10-13M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 product revenue $59.9M (+10% YoY); total revenue $75.5M vs $59.1M YoY including $15.6M royalty.","GAAP net income Q4 2025 $13.4M ($0.27 basic) vs $19.3M ($0.39) YoY; non-GAAP adjusted net income $15.1M ($0.30).","Full year 2025 total revenue $228.4M; GAAP net income $31.1M ($0.62) vs $30.3M ($0.62) YoY.","Cash, equivalents & marketable securities $97.5M; total debt reduced to $22.5M from $67.0M at end of 2024.","FY2026 guidance: net product revenue $194-198M; total revenue $214-221M; net income $10-13M, excluding valuation allowance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":228371000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119878,"accession_number":"0001437749-25-033604","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma raises 2025 guidance; Q3 GAAP net income $8.8M vs $20.3M YoY on lower royalty revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP net income $8.8M ($0.17 diluted) vs $20.3M ($0.41) YoY; non-GAAP adj. net income $10.5M ($0.21) vs $22.4M ($0.46).","Q3 product revenue $51.9M (vs $56.1M); total revenue $54.5M (vs $80.5M) driven by lower royalty from China licensee.","Updated FY2025 guidance: product revenue $198-200M, total revenue $220-223M, net income $27-29M (all raised from prior).","Cash & securities $94.4M at Sep 30, 2025; operating cash flow $9.7M in Q3.","Interim data from ALISCA-Breast1 and ALISCA-Lung1 alisertib trials expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":152918000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136443,"accession_number":"0001437749-25-025463","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotechnology Q2 net income $5.9M vs year-ago loss; revenue rises to $52.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.12 vs $(0.09) loss; adjusted EPS $0.15 vs $(0.05) loss.","Net product revenue $49.2M (+11% YoY); total revenue $52.4M (+11% YoY).","Q3 2025 guidance: net product revenue $46–48M, total revenue $48–51M, net income $2–4M.","Full-year 2025 revenue outlook reaffirmed at $212–222M; gross-to-net adjustment raised to 21.5–22.0%.","Cash & equivalents $96M; key milestones: alisertib interim data in Q4 2025 for two Phase II trials."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":98443000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153603,"accession_number":"0001437749-25-021153","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Puma Biotechnology amends bylaws to align with Delaware law updates","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted Fifth Amended and Restated Bylaws on June 19, 2025.","Changes primarily reflect updates to Delaware General Corporation Law.","Includes conforming, ministerial, and other related revisions.","No substantive operational or financial changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153602,"accession_number":"0001437749-25-020321","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Puma Biotechnology shareholders elect directors, ratify KPMG, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eight directors elected; Troy E. Wilson received 24.3M for, 10.7M withheld, the largest withhold among nominees.","Ratification of KPMG as independent auditor for FY2025 passed with 40.7M for, 0.7M against.","Advisory vote on named executive officer compensation approved with 32.6M for, 1.7M against, 0.7M abstain.","6.5M broker non-votes were recorded on director election and say-on-pay, not on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153601,"accession_number":"0001437749-25-015648","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Puma Biotechnology terminates CCO Jeff J. Ludwig; no replacement named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terminated Jeff J. Ludwig as Chief Commercial Officer and employee on May 8, 2025.","Mr. Ludwig may receive severance per his employment offer letter contingent on signing a release within 60 days.","Company will not appoint a new CCO; responsibilities absorbed by existing sales and marketing personnel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153600,"accession_number":"0001437749-25-015514","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma swings to Q1 profit; NERLYNX revenue up 7% to $43.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $3.0M ($0.06 EPS) vs net loss $4.8M ($0.10 loss) in Q1 2024.","Non-GAAP adjusted net income $5.0M ($0.10 EPS) vs adjusted loss $2.4M.","Product revenue $43.1M (+7% YoY), royalty revenue $2.9M.","Q2 2025 guidance: net product revenue $48-50M, net income $4-6M.","Cash & securities $93.2M at Mar 31, down from $101.0M at Dec 31."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":46007000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172311,"accession_number":"0001437749-25-005477","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotechnology reports Q4 GAAP net income $19.3M ($0.39 EPS); guides FY2025 net income $23-28M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue net $54.4M (up from $53.2M YoY); full year $195.2M (down from $203.1M).","GAAP net income $30.3M ($0.62/share) for FY2024 vs. $21.6M ($0.46) in FY2023.","Non-GAAP adjusted net income $38.5M ($0.79/share) for FY2024 vs. $31.8M ($0.68) in FY2023.","Cash and securities $101M at Dec 31, 2024; operating cash flow $38.9M for FY2024.","FY2025 guidance: net product revenue $192-198M; net income $23-28M (excludes valuation allowance)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":230468000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189305,"accession_number":"0001437749-24-033929","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotech Q3 net income $20.3M vs $5.8M YoY; raises FY 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $56.1M (+8.7% YoY); total revenue $80.5M including $24.4M royalty revenue.","GAAP EPS $0.41 diluted; adjusted non-GAAP EPS $0.45 diluted.","FY 2024 net product revenue guidance raised to $187-190M (from $183-190M); net income raised to $15-17M.","Cash & securities $97M at Sept 30; operating cash flow $11M in Q3.","Phase II alisertib trials in SCLC and breast cancer on track; interim data expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":171391000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205799,"accession_number":"0001437749-24-029206","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Puma reports judge invalidated Tagrisso patents; Wyeth appeals Sept 12","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury awarded $107.5M for past infringement of '314 and '162 patents through Dec 2023.","Judge granted AstraZeneca's motion, ruling patents invalid for lack of enablement/written description.","Wyeth filed notice of appeal on Sept 12, 2024, challenging the invalidity ruling and other adverse orders.","Puma was dismissed as plaintiff but retains contractual rights to recover damages under Pfizer agreement.","Puma respectfully disagrees with the invalidity ruling; post-trial motions for supplemental damages and ongoing royalties pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205798,"accession_number":"0001437749-24-026953","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Court invalidates Puma's patents in Tagrisso suit, overturns $107.5M jury award","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury found Tagrisso infringed Puma's patents, awarded $107.5M in damages.","Judge overturned verdict, ruling patents invalid under §112 for lack of enablement/written description.","Final judgment entered; Puma can appeal by Sept 13, 2024.","Puma dismissed as plaintiff but retains contractual rights to damages via Wyeth; ruling affects potential recovery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205797,"accession_number":"0001437749-24-025027","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Puma Biotechnology wins patent suit vs AstraZeneca; $107.5M jury award upheld in bench trial","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury found Tagrisso infringes Wyeth's patents; damages of $107.5M for past infringement through Dec 31, 2023.","Bench trial on equitable claims ruled in Wyeth's favor; all AstraZeneca defenses rejected.","Puma maintains contractual rights to recover monetary damages under license with Pfizer.","Post-trial motions pending; AstraZeneca seeks new trial, Wyeth seeks supplemental damages and ongoing royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205796,"accession_number":"0001437749-24-024297","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Q2 NERLYNX revenue $44.4M (-14% YoY); GAAP net loss $4.5M vs profit $2.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 product revenue $44.4M (down from $51.6M in Q2 2023); total revenue $47.1M incl $2.7M royalties.","GAAP net loss $4.5M ($0.09 loss per share) vs net income $2.1M ($0.05 EPS) in Q2 2023.","Non-GAAP adjusted net loss $2.5M ($0.05 loss per share) vs adjusted net income $4.6M ($0.10 EPS).","Cash & equivalents $96.8M at June 30, 2024; net cash from ops $1.0M in Q2.","FY2024 guidance: net product revenue $183-190M, net income $12-15M; Q3 net product revenue $50-53M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":90849000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222774,"accession_number":"0001437749-24-021086","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Puma Biotechnology shareholders approve 3M share increase for equity plan, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase shares under 2011 plan by 3M to 17,529,412; ISO grants extended to March 2034.","All eight director nominees elected: Auerbach, Cesano, Dorval, Miller, Moyes, Senderowicz, Stuglik, Wilson.","Ratified KPMG as independent auditor for fiscal 2024 with 40.2M votes for.","Advisory say-on-pay approved with 30.7M for; board adopts annual frequency for future votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222773,"accession_number":"0001437749-24-017504","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jury awards Puma/Wyeth $107.5M in Tagrisso patent infringement case vs AstraZeneca","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury found '314 and '162 patents infringed and not invalid; damages $107.5M for past acts.","Puma was dismissed as plaintiff but retains contractual right to recover damages under Pfizer license.","Bench trial on equitable defenses (unclean hands, patent misuse) set for June 17-18, 20, 2024.","Further proceedings will determine ongoing royalty rate through patent term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222772,"accession_number":"0001437749-24-014382","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotech Q1 net loss $4.8M vs prior year net income; NERLYNX revenue down 14%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $40.3M (Q1 2023: $46.8M); total revenue $43.8M including $3.5M royalties.","GAAP net loss $0.10/shr; non-GAAP adjusted net loss $0.05/shr vs adjusted net income $0.09/shr in Q1 2023.","Cash, cash equivalents and marketable securities $107.2M at March 31, 2024; operating cash flow $11.3M.","Q2 2024 guidance: net product revenue $43-45M, net loss $(6)-(9)M; FY2024: product revenue $183-190M, net income $12-15M.","Initiated alisertib Phase II trial in small cell lung cancer (ALISCA-Lung1); key milestones through Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":43766000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242259,"accession_number":"0001437749-24-008508","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Puma partially dismissed as plaintiff in Tagrisso patent suit; trial set May 13","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court denied AstraZeneca's motions for patent invalidity and summary judgment of non-infringement.","AstraZeneca's motion to dismiss Puma as plaintiff granted on standing grounds; Puma remains counterclaim-defendant.","Puma retains contractual rights under Pfizer license to seek monetary damages in the case.","Jury trial scheduled for May 13, 2024 in Delaware federal court.","Suit alleges Tagrisso infringes patents licensed exclusively to Puma; Wyeth continues as co-plaintiff."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242258,"accession_number":"0001437749-24-006099","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotechnology reports Q4 GAAP net income of $12.3M; guides Q1 2024 net loss of $10-12M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue net Q4 $53.2M (flat YoY); full year $203.1M, up from $200.0M.","GAAP net income Q4 $12.3M ($0.26/diluted) vs net loss $5.6M in Q4 2022.","Non-GAAP adjusted net income Q4 $14.8M ($0.31/share) vs adjusted net loss $3.0M.","Cash and marketable securities $96.0M at Dec 31, 2023, up from $81.1M a year ago.","Guidance: Q1 2024 net product revenue $38-40M, net loss $10-12M; FY2024 net income $12-15M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":235637000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242257,"accession_number":"0001437749-24-001581","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Puma Biotechnology presents at B. Riley Oncology Conference; no material new information disclosed.","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation at B. Riley Securities 4th Annual Oncology Conference on January 18, 2024.","Chairman, President and CEO Alan H. Auerbach to present.","Exhibit 99.1 presentation not included as extractable text; specifics unavailable.","No financial or operational updates disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}